{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for amphotericin root_names_stdName in Standardized Name (approximate match)
Status:
Possibly Marketed Outside US
Source:
BLA125127
(2005)
Source URL:
First approved in 2005
Source:
BLA125127
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
BLA125020
(2003)
Source URL:
First approved in 2003
Source:
BLA125020
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
BLA125020
(2003)
Source URL:
First approved in 2003
Source:
BLA125020
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
BLA125020
(2003)
Source URL:
First approved in 2003
Source:
BLA125020
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
BLA125034
(2003)
Source URL:
First approved in 2003
Source:
BLA125034
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
M012
(2024)
Source URL:
First approved in 1999
Source:
ANDA209886
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
BLA103914
(1980)
Source URL:
First approved in 1980
Source:
BLA103914
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
505G(a)(3)
(2025)
Source URL:
First approved in 1956
Source:
ANDA091382
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT01531140: Phase 4 Interventional Completed Colonoscopy Preparation
(2010)
Source URL:
First approved in 1956
Source:
M007
Source URL:
Class:
STRUCTURALLY DIVERSE
Targets:
Conditions:
Sennosides are hydroxyanthracene glycosides derived from Senna leaves. They have been used as natural, safe time-tested laxatives in traditional as well as modern systems of medicine. Sennosides (Senna) is a medication used to treat constipation and empty the large intestine before surgery. The medication is taken by mouth or via the rectum. It typically begins working in minutes when given by rectum and within twelve hours when given by mouth. It is a weaker laxative than bisacodyl or castor oil. Senna is an FDA-approved nonprescription drug for adults and children ages 2 years and older. It is also used for bowel preparation before colonoscopy and diagnostic imaging.
Status:
Possibly Marketed Outside US
Class:
STRUCTURALLY DIVERSE